 |
|
|
| |
Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults With HIV-1: Week 240 Results of the Phase 3 BRIGHTE Study
|
| |
| |
24th IAC July 29-Aug 1 2022
Judith Aberg,1 Bronagh Shepherd,2 Marcia Wang,3 Jose V. Madruga,4 Fernando Mendo Urbina,5 Christine Katlama,6 Shannon Schrader,7 Joseph J. Eron,8 Shiven Chabria,9
Andrew Clark,10 Amy Pierce,11 Max Lataillade,9 Peter Ackerman9*
1Icahn School of Medicine at Mount Sinai, New York, NY, USA; 2GSK, Brentford, UK; 3GSK, Upper Providence, PA, USA; 4CRT-DST/AIDS SP, São Paulo, Brazil; 5Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru; 6AP-HP, Hôpital Pitié-Salpêtrière, Service de Maladies Infectieuses et Tropicales, INSERM-Sorbonne Universités, Paris, France; 7Schrader Clinic, Houston, TX, USA; 8University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA; 9ViiV Healthcare, Branford, CT, USA; 10ViiV Healthcare, Brentford, UK; 11ViiV Healthcare, Durham, NC, USA
*Employee of ViiV Healthcare at the time of the study.
|
| |
|
|
|
|
|
